The global hypertensive heart diseases market is anticipated to grow at a CAGR of around 3.5% during the forecast period (2021-2027). The prevalence of hypertensive heart disease in North America is the major factor driving the growth of the region. The growing aging population in the US accelerating the demand for hypertensive heart disease treatments and drugs. As per the Urban Institutes, the aging population over 65 in America is expected to be double over the next 40 years, reaching 80 million in 2040. Hypertension is the major cause of heart disease in the US population. In 2018, nearly half a million deaths in the US included hypertension as a primary or contributing cause as per the CDC estimates. According to the CDC, hypertension in the US costs around $48.6 billion every year. This cost includes the cost related to the medication, healthcare services, and other related healthcare services.
Browse the full report description of "Global Hypertensive Heart Diseases Market Size, Share & Trends Analysis Report By Diagnosis (Electrocardiogram, Echocardiogram, Coronary Angiography, Others) By Therapeutic (Drugs, and Surgery) Forecast 2021-2027" at https://www.omrglobal.com/industry-reports/hypertensive-heart-disease-market
The rising healthcare expenditure, and government grants, and rising awareness about hypertension are also the factors accelerating the growth of the market. The US spending on healthcare is more than any other country. The federal government is the major source of US healthcare spending. According to the Tax Policy Center, in 2019, around $1.2 trillion on healthcare was spend by the US federal government. Whereas, as per the Canadian Institute for Health Information, in 2019, Canada spent nearly $265.5 billion as healthcare expenditure. Which was 11.5% of Canada’s gross domestic product (GDP). Moreover, regional growth is also impacted by the presence of major players. The various strategies such as mergers and acquisition, new product launch, and expenditure on R&D adopted by the major players has accelerated the growth of the market.
Market Coverage
o By Diagnosis
o By Therapeutic
o North America
o Europe
o Asia-Pacific
o Rest of the World
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Hypertensive Heart Diseases Market Report Segment
By Diagnosis
By Therapeutics
o Thiazide Diuretics
o Beta-Blockers
o Angiotensin-Converting Enzyme (ACE) Inhibitors
o Angiotensin II Receptor Blockers (ARB)
o Calcium Channel Blockers
o Others (Renin Inhibitors)
o Coronary Artery Bypass Surgery
o Transmyocardial Laser Revascularization
o Heart Transplant
Global Hypertensive Heart Diseases Market Report by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/hypertensive-heart-disease-market